drugset

drugset / Trial / NCT03710122

Vancomycin for Primary Sclerosing Cholangitis

NCT03710122 ↗

Phase 2/3 Terminated 102 enrolled Elizabeth Carey Arizona State University · collab

RandomizedParallel-groupTriple-blindTreatment

Summary

To find out if vancomycin is a safe and effective therapy for primary sclerosing cholangitis. Funding Source - FDA OOPD

Timeline

Start: 2020-01-23
Primary completion: 2025-03-03
Completion: 2025-03-20

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Vancomycin	Other / unclassified	—	—

Indications